In the News
With details on lead sialoglycan degrader in place, Palleon raises $100M series B
BioCentury
Palleon battalion bags $100M series B for glycan push
BioWorld
Palleon Pharmaceuticals secures $100m in Series B funding
Pharmaceutical Technology
Jim Broderick reels in a $100M Series B to explore a ‘new and big’ angle of immune regulation
Endpoints
Palleon’s first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO
Endpoints
Beyond PROTACs and the proteasome: broadening the TAC toolbox
BioCentury
Carolyn Bertozzi’s glycorevolution
Chemical & Engineering News
SIGLECs go from homing beacons to next-generation checkpoints
BioCentury
Glycoscience fuels a new breed of cancer immunotherapy
Chemical & Engineering News
Carolyn Bertozzi on becoming a chemical biologist/glycobiologist
The Long Run with Luke Timmerman
Palleon: Sweeter checkpoints
BioCentury
The Biology of Sugars Points to a Sweet Strategy for Treating Cancer
Scientific American
Startup Palleon has a sweet plan for cancer immunotherapy
FierceBiotech
Cancer cells cast a sweet spell on the immune system
ScienceNews